Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM)

Historical Holders from Q1 2021 to Q3 2025

Symbol
CGEM on Nasdaq
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
58.8M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
61.1M
Holdings value
$362M
% of all portfolios
0.002%
Grand Portfolio weight change
0%
Number of holders
142
Number of buys
82
Number of sells
-62
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Lynx1 Capital Management LP 14.5% +100% $50.7M $24.6M 8.55M +94.3% Lynx1 Capital Management LP 08 Oct 2025
VANGUARD GROUP INC 4.98% $17.5M 2.94M The Vanguard Group 30 Sep 2025
Flynn James E 4.95% $17.4M 2.93M Deerfield Mgmt, L.P. 30 Sep 2025
FRANKLIN RESOURCES INC 3.8% $17.8M 2.19M Franklin Resources, Inc. 30 Sep 2024
CITADEL ADVISORS LLC 3.4% -34% $11.8M -$6.05M 1.99M -33.9% Kenneth Griffin 30 Sep 2025

Institutional Holders of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 61.1M $362M -$12.5M $5.93 142
2025 Q2 62.6M $471M -$15.6M $7.53 141
2025 Q1 64.7M $490M -$25.8M $7.57 145
2024 Q4 65.6M $799M -$43.3M $12.18 144
2024 Q3 65M $1.09B -$1.19M $16.74 136
2024 Q2 62.9M $1.1B +$412M $17.44 134
2024 Q1 39.4M $671M +$49.2M $17.04 113
2023 Q4 36.9M $376M +$27M $10.19 110
2023 Q3 38M $344M +$11M $9.05 104
2023 Q2 36.7M $395M +$48.7M $10.76 102
2023 Q1 32.2M $329M -$56.3M $10.23 97
2022 Q4 37.7M $398M +$5.32M $10.55 94
2022 Q3 37M $475M -$7.04M $12.82 94
2022 Q2 37.6M $482M +$20.4M $12.82 81
2022 Q1 36.8M $385M +$4.82M $10.47 77
2021 Q4 36.4M $560M +$6.27M $15.43 74
2021 Q3 33.9M $762M +$33.8M $22.57 63
2021 Q2 32.3M $829M -$17.7M $25.75 70
2021 Q1 31.3M $1.3B +$1.3B $41.67 70